ROIV
HEALTHCARERoivant Sciences Ltd
AI Insight
What's Moving ROIV Today?
No stock-specific AI insight has been generated for ROIV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.71$32.80
$34.01
Fundamentals
Market Cap$22.5B
P/E Ratio—
EPS$-0.54
Dividend Yield—
Dividend / Share—
ROE-7.6%
Profit Margin—
Debt / Equity—
Trading
Volume10.3M
Avg Volume (10D)—
Shares Outstanding719.3M
ROIV News
28 articles- Roivant Sciences stock hits all-time high at 32.8 USD By Investing.comInvesting.com Canada·Jun 24, 2026
- Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline ProgressSimply Wall Street·Jun 19, 2026
- Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold TerritoryYahoo Finance·Jun 17, 2026
- Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline DevelopmentYahoo Finance·Jun 11, 2026
- Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)Yahoo Finance·Jun 9, 2026
- Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price MomentumYahoo Finance·May 26, 2026
- TD Cowen Raises its Price Target on Roivant Sciences (ROIV)Yahoo Finance·May 25, 2026
- Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)Yahoo Finance·May 25, 2026
- [Form 4] Roivant Sciences Ltd. Insider Trading ActivityStock Titan·May 22, 2026
- Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors?Simply Wall Street·May 22, 2026
- Roivant (ROIV) Climbs 15% on Swing to ProfitsYahoo Finance·May 21, 2026
- 2 Biotech Stocks Are Surging Today Thanks to This Arthritis DrugYahoo Finance·May 20, 2026
- These Two Biotech Stocks Rocketed — And One Just Broke OutYahoo Finance·May 20, 2026
- Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ...Yahoo Finance·May 20, 2026
- Roivant (ROIV) Q4 2025 Earnings TranscriptMotley Fool·May 20, 2026
- Roivant Sciences Q4 Earnings Call HighlightsMarketbeat·May 20, 2026
- Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)Advfn·May 20, 2026
- Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·May 20, 2026
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business UpdateYahoo Finance·May 20, 2026
- Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing updateBiopharmadive·May 20, 2026
- How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib MilestonesYahoo Finance·May 20, 2026
- Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's WhyYahoo Finance·May 19, 2026
- Hedge Fund Wagers $36 Million on Biotech Denali After First FDA ApprovalMotley Fool·May 18, 2026
- Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?Motley Fool·May 18, 2026
- Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation GapSimply Wall Street·May 8, 2026
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
- Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)GlobeNewswire Inc.·Apr 2, 2026
- New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in DermatomyositisGlobeNewswire Inc.·Mar 28, 2026
All 28 articles loaded
Price Data
Open$32.25
Previous Close$32.21
Day High$34.51
Day Low$32.00
52 Week High$32.80
52 Week Low$10.71
52-Week Range
$10.71$32.80
$34.01
Fundamentals
Market Cap$22.5B
P/E Ratio—
EPS$-0.54
Dividend Yield—
Dividend / Share—
ROE-7.6%
Profit Margin—
Debt / Equity—
Trading
Volume10.3M
Avg Volume (10D)—
Shares Outstanding719.3M
About Roivant Sciences Ltd
Roivant Sciences Ltd (ROIV) is an innovative biopharmaceutical company dedicated to revolutionizing the drug development and commercialization landscape through its unique business model and advanced technologies. The company boasts a robust pipeline that targets significant unmet medical needs across neurology, immunology, and rare diseases, positioning itself to efficiently navigate the complexities of drug development while minimizing costs. Led by a seasoned team and supported by strategic partnerships, Roivant aims to deliver both financial growth and enhanced patient outcomes, making it a compelling opportunity for institutional investors.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—